Apogee Therapeutics (APGE) Competitors $48.09 +0.88 (+1.86%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends APGE vs. ASND, RVMD, LNTH, NUVL, LEGN, ELAN, BPMC, CYTK, TGTX, and VKTXShould you be buying Apogee Therapeutics stock or one of its competitors? The main competitors of Apogee Therapeutics include Ascendis Pharma A/S (ASND), Revolution Medicines (RVMD), Lantheus (LNTH), Nuvalent (NUVL), Legend Biotech (LEGN), Elanco Animal Health (ELAN), Blueprint Medicines (BPMC), Cytokinetics (CYTK), TG Therapeutics (TGTX), and Viking Therapeutics (VKTX). These companies are all part of the "pharmaceutical products" industry. Apogee Therapeutics vs. Ascendis Pharma A/S Revolution Medicines Lantheus Nuvalent Legend Biotech Elanco Animal Health Blueprint Medicines Cytokinetics TG Therapeutics Viking Therapeutics Apogee Therapeutics (NASDAQ:APGE) and Ascendis Pharma A/S (NASDAQ:ASND) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, community ranking, dividends and institutional ownership. Which has better earnings & valuation, APGE or ASND? Apogee Therapeutics has higher earnings, but lower revenue than Ascendis Pharma A/S. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioApogee TherapeuticsN/AN/A-$83.99M-$2.42-19.87Ascendis Pharma A/S$327.43M25.98-$521.07M-$8.08-17.36 Which has more volatility and risk, APGE or ASND? Apogee Therapeutics has a beta of 2.3, meaning that its stock price is 130% more volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Do analysts prefer APGE or ASND? Apogee Therapeutics presently has a consensus price target of $83.88, indicating a potential upside of 74.41%. Ascendis Pharma A/S has a consensus price target of $191.77, indicating a potential upside of 36.69%. Given Apogee Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Apogee Therapeutics is more favorable than Ascendis Pharma A/S.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apogee Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Ascendis Pharma A/S 0 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.92 Does the MarketBeat Community believe in APGE or ASND? Ascendis Pharma A/S received 415 more outperform votes than Apogee Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Apogee Therapeutics an outperform vote while only 66.52% of users gave Ascendis Pharma A/S an outperform vote. CompanyUnderperformOutperformApogee TherapeuticsOutperform Votes24100.00% Underperform VotesNo VotesAscendis Pharma A/SOutperform Votes43966.52% Underperform Votes22133.48% Do institutionals and insiders hold more shares of APGE or ASND? 79.0% of Apogee Therapeutics shares are held by institutional investors. 36.1% of Apogee Therapeutics shares are held by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media favor APGE or ASND? In the previous week, Ascendis Pharma A/S had 1 more articles in the media than Apogee Therapeutics. MarketBeat recorded 19 mentions for Ascendis Pharma A/S and 18 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 0.94 beat Ascendis Pharma A/S's score of 0.79 indicating that Apogee Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apogee Therapeutics 10 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 7 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is APGE or ASND more profitable? Apogee Therapeutics has a net margin of 0.00% compared to Ascendis Pharma A/S's net margin of -130.33%. Ascendis Pharma A/S's return on equity of 0.00% beat Apogee Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Apogee TherapeuticsN/A -21.81% -20.94% Ascendis Pharma A/S -130.33%N/A -48.77% SummaryApogee Therapeutics beats Ascendis Pharma A/S on 10 of the 17 factors compared between the two stocks. Ad Porter & CompanyMusk threatens Liberal’s fake “energy crisis”Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.To get the full details on the fake “energy crisis” of America, watch this now Get Apogee Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APGE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APGE vs. The Competition Export to ExcelMetricApogee TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.17B$2.98B$5.18B$9.31BDividend YieldN/A1.85%4.78%4.06%P/E Ratio-19.8745.47130.2217.53Price / SalesN/A420.221,246.14139.51Price / CashN/A182.1341.2337.95Price / Book6.413.924.884.92Net Income-$83.99M-$42.03M$119.65M$225.78M7 Day Performance-1.39%-3.37%16.62%-1.56%1 Month Performance6.09%7.95%16.34%6.68%1 Year Performance110.37%21.00%35.38%22.48% Apogee Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APGEApogee Therapeutics2.729 of 5 stars$48.09+1.9%$83.88+74.4%+110.6%$2.17BN/A-19.8791Insider TradeShort Interest ↑News CoverageASNDAscendis Pharma A/S3.2197 of 5 stars$136.47+5.1%$191.77+40.5%+16.0%$8.28B$327.43M-16.52640Short Interest ↑RVMDRevolution Medicines4.6632 of 5 stars$44.68-0.7%$63.67+42.5%+69.6%$7.52B$11.58M-12.54443Positive NewsLNTHLantheus4.4014 of 5 stars$94.50+1.6%$130.00+37.6%+21.9%$6.57B$1.50B15.42834Positive NewsNUVLNuvalent2.3475 of 5 stars$86.53-0.4%$112.60+30.1%+9.7%$6.15BN/A-25.0340Positive NewsLEGNLegend Biotech1.6722 of 5 stars$33.61-4.3%$81.54+142.6%-43.4%$6.14B$520.18M-36.971,800ELANElanco Animal Health4.2802 of 5 stars$12.18+0.7%$16.75+37.5%-10.5%$6.02B$4.45B30.259,300BPMCBlueprint Medicines2.9172 of 5 stars$95.54+2.5%$122.11+27.8%+9.7%$5.92B$434.42M-45.28640Insider TradeShort Interest ↑CYTKCytokinetics3.9886 of 5 stars$49.20+1.1%$83.93+70.6%+32.5%$5.81B$3.22M-9.04250TGTXTG Therapeutics3.8183 of 5 stars$34.75+8.5%$40.67+17.0%+81.7%$5.41B$233.66M-320.17290Positive NewsVKTXViking Therapeutics4.2798 of 5 stars$48.10+2.3%$106.75+121.9%+147.1%$5.36BN/A-51.5620 Related Companies and Tools Related Companies ASND Competitors RVMD Competitors LNTH Competitors NUVL Competitors LEGN Competitors ELAN Competitors BPMC Competitors CYTK Competitors TGTX Competitors VKTX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:APGE) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apogee Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apogee Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
